title: Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial.
abstract: A multicentre trial (11 nephrology centres) was carried out to test the effects of ibopamine, an orally active dopamine-like drug, on the progression of chronic renal failure. For a 2-year period 189 chronic renal failure patients (serum creatinine level 1.5-4.0 mg/dl) were observed. They were homogeneous for basic nephropathy, degree of residual renal function, blood pressure, and proteinuria. The patients were randomly divided into two groups: 96 took ibopamine at a dosage of 100 mg/day (group A) and 93 served as controls (group B). All were on a low-protein diet (mean 0.8 g/kg body weight). By the end of the observation period, the rate of decrease of the renal function indexes in time proved significantly slower (1.8 times) in group A than in group B. The survival curves for renal function (pre-established end points were creatinine level increases equal to or > 20% and equal to or > 40% of the basal values) proved significantly better (p < 0.02 and p < 0.002 respectively) in group A than in group B. The mean plasma creatinine values rose by 17% in group A and by 36% in group B. The creatinine clearance decreased by 5% in treated patients and by 14% in the controls. Statistical analysis ruled out any possible centre effect. The trial suggests that low-dosage ibopamine administration may be used as a valid and safe pharmacological adjunct for retarding the progression of renal failure in patients with mild or moderate chronic renal impairment.
authors.affiliation: Chair of Nephrology, University of Bologna, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Stefoni
authors.forename: G
authors.initials: G
authors.lastname: Mosconi
authors.forename: G
authors.initials: G
authors.lastname: La Manna
authors.forename: V
authors.initials: V
authors.lastname: Bonomini
authors.forename: V
authors.initials: V
authors.lastname: Mioli
authors.forename: E
authors.initials: E
authors.lastname: Fanciulli
authors.forename: C
authors.initials: C
authors.lastname: Feletti
authors.forename: D
authors.initials: D
authors.lastname: Docci
authors.forename: P
authors.initials: P
authors.lastname: Cappelli
authors.forename: M
authors.initials: M
authors.lastname: Bonomini
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: P
authors.initials: P
authors.lastname: Marai
authors.forename: G
authors.initials: G
authors.lastname: Bazzato
authors.forename: A
authors.initials: A
authors.lastname: Fracasso
authors.forename: D
authors.initials: D
authors.lastname: Brancaccio
authors.forename: C
authors.initials: C
authors.lastname: Galmozzi
authors.forename: L
authors.initials: L
authors.lastname: Scarpioni
authors.forename: E
authors.initials: E
authors.lastname: Sverzellati
authors.forename: G B
authors.initials: GB
authors.lastname: Sorba
authors.forename: M
authors.initials: M
authors.lastname: Cossu
authors.forename: G
authors.initials: G
authors.lastname: Piccoli
authors.forename: D
authors.initials: D
authors.lastname: Roccatello
authors.forename: L
authors.initials: L
authors.lastname: Oldrizzi
authors.forename: V
authors.initials: V
authors.lastname: De Biase
authors.forename: A A
authors.initials: AA
authors.lastname: Bignamini
mesh_terms: D000293:Adolescent; D000368:Aged; D003404:Creatinine / Q000378:metabolism; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008875:Middle Aged
chemical_list: D018491:Dopamine Agonists; C023487:ibopamine; D003404:Creatinine; D003846:Deoxyepinephrine